Imiquimod – 500 mg

Brand:
Cayman
CAS:
99011-02-6
Storage:
-20
UN-No:
Non-Hazardous - 2811 / 6.1

Imiquimod is an imidazoquinoline agonist of toll-like receptor 7 (TLR7; EC50 = 2.12 μM).{23982} It increases TNF-α and IL-12 p40 production in IFN-γ-treated murine peritoneal macrophages in a concentration- and MyD88-dependent manner.{23979} Topical application of imiquimod (30 μl of 5% cream) increases TNF and IFN levels at the application site in hairless mice.{43540} Imiquimod dose-dependently increases serum levels of IFN-α in mice when administered by gavage.{43541} It reduces tumor growth in an MC-26 model of murine colon cancer when administered at a dose of 30 mg/kg every three days. Imiquimod (5 mg/kg, intravaginally, twice daily) reduces vaginal viral titer and lesion formation in a guinea pig model of genital HSV-2 infection.{43542} Formulations containing imiquimod have been used in the treatment of actinic keratosis, superficial basal cell carcinoma, and external genital warts.  

 

SKU: - Category:

Description

A TLR7 agonist (EC50 = 2.12 μM); increases TNF-α and IL-12 p40 production in IFN-γ-treated murine peritoneal macrophages in a concentration- and MyD88-dependent manner; topical application of a 5% cream increases TNF and IFN levels at the application site in hairless mice; dose-dependently increases serum levels of IFN-α in mice when administered by gavage; reduces tumor growth in an MC-26 model of murine colon cancer at 30 mg/kg every three days; reduces vaginal viral titer and lesion formation in a guinea pig model of genital HSV-2 infection at 5 mg/kg, intravaginally, twice daily


Formal name: 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine

Synonyms:  R-837|S-26308|TMX 101

Molecular weight: 240.3

CAS: 99011-02-6

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Cancer||Research Area|Immunology & Inflammation|Innate Immunity|Pattern Recognition||Research Area|Infectious Disease|Viral Diseases|HSV